NASDAQ: CASI | 中文 | Contact Us

CASI Pharmaceuticals

CASI News

CASI Hosts Nobel Laureate James P. Allison

September 10, 2019

CASI hosts a key opinion leader (KOL) symposium addressing innovations in cancer immunotherapy. A replay of Nobel Laureate James P. Allison Discussion on Immunotherapy Checkpoint Blockade in Cancer Therapy can be found at https://www.youtube.com/channel/UC5IBDAqhTqt5esL9r3dgQRQ.


Evomela Commercially Available In China

August 12, 2019

EVOMELA® received market approval by the China National Medical Products Administration (NMPA) for use as high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplant in patients with multiple myeloma, and as a palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. It is the only approved and commercially available melphalan product in China.

Press Release

December 03, 2019

CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 (CD19 CAR-T) Clinical Trial Applications

Read More

Press Release

November 12, 2019

CASI Pharmaceuticals Announces Third Quarter 2019 Financial Results

Read More

Press Release

November 07, 2019

CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement For Octreotide Long Acting Injectable (LAI) Microsphere For Neuroendocrine Cancers And Acromegaly

Read More

View All Email Alerts |

U.S. FDA-Approved Products In-Licensed for the Greater China Region

Evomela®

Multiple Myeloma

Zevalin®

Non-Hodgkin's Lymphoma

Marqibo®

Acute Lymphoblastic Leukemia

Pre-Clinical Drug Candidates

CID-103

Multiple Myeloma

CNTC19

Hematological Malignancies
Learn more about our product pipeline

EVOMELA® (melphalan) for Injection, MARQIBO® (vincristine sulfate LIPOSOME injection), and ZEVALIN® (ibritumomab tiuxetan) are proprietary to Acrotech Biopharma LLC and its affiliates.

CASI Pharmaceuticals

© 2019 CASI Pharmaceuticals Inc.
All Rights Reserved.